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Objective: Long-term outcomes after participation in a structured diabetes treatment and 
teaching program (DTTP) for patients with diabetes without insulin use, primarily based upon 
postprandial urine glucose self-monitoring (UGSM).
Methods: A total of 126 patients took part in the DTTP in a university outpatient department 
in 2004–2005. We re-evaluated 119 (94.4%) at baseline and at 6 months, 12 months, and 
24 months. Hemoglobin A1c (HbA1c) was DCCT adjusted.
Results: HbA1c decreased significantly 6 months after education from 7.33% (±1.59%) to 6.89% 
(±0.98%; P = 0.001 versus baseline) and was maintained for up to 12 months (7.02% ± 1.07%; 
P = 0.017 versus baseline) as well as up to 24 months (6.96% ± 1.06%; P = 0.005 versus base-
line). Weight decreased from 92.5 kg at baseline to 90.3 kg at 24 months (P = 0.014). A total 
of 36.5% of patients not on insulin therapy preferred UGSM, whereas 23.5% preferred blood 
glucose monitoring, at 24 months. Glucose control was similar in both groups at 24 months 
(HbA1c UGSM 7.03 versus blood glucose monitoring 6.97%; P = 0.807).
Conclusion: Participation in the DTTP resulted in long-term behavior modification. HbA1c 
of patients without insulin met the target 24 months after the DTTP, irrespective of the type of 
glucose self-monitoring.
Keywords: diabetes mellitus type 2, treatment and teaching program, patient education, HbA1c, 
body weight
Introduction
Type 2 diabetes mellitus affects about 5% of the German population.1 Eighty percent of 
patients with type 2 diabetes are treated with diet or oral antiglycemic drugs (OADs).2 
For successful treatment of patients with diabetes, we have different therapy options, 
such as modification of eating behavior and physical exercise, OADs, and insulin. 
A necessary prerequisite of successful treatment is the active involvement of the 
patients in their treatment. Continuous adjustment of nutrition, exercise, and medication 
according to the patient’s insulin secretion and/or insulin resistance is necessary for 
the treatment of diabetes mellitus. Therefore, diabetes education is crucial, whatever 
therapeutic option is chosen.
Diabetes education contributes to better metabolic control or to preservation of good 
control.3,4 However, some reviews on the effectiveness of education in type 2 diabetes 
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have also reported positive effects on patient   knowledge, 
  self-care behavior, and psychological outcomes.5–7 The dura-
tion of effective diabetes education programs is controversial. 
The trials evaluating the majority of these treatment and 
teaching programs have only a relatively short follow-up 
period of 6–12 months.3,4,8 Another controversial topic is 
whether blood glucose self-monitoring (BGSM) has advan-
tages over urine glucose self-monitoring (UGSM) in patients 
not requiring insulin therapy.9–12
A structured diabetes treatment and teaching program 
(DTTP) for patients with type 2 diabetes not on insulin therapy 
was implemented in the German health care system several 
years ago. This program comprised four sessions of  90 minutes 
each. It is primarily based upon postprandial UGSM. The 
first evaluation of this DTTP in Germany with a follow-up of 
12 months was published 20 years ago.3 Another evaluation 
from Austria published in 1995 had a follow-up of 6 months.4
However, longer follow-up periods have hitherto not been 
studied. We evaluated outcomes 24 months after participa-
tion in this DTTP.
Patients and methods
A total of 126 patients with type 2 diabetes mellitus not requir-
ing insulin therapy took part in the DTTP in 2004–2005 in 
the outpatient department for endocrinology and metabolic 
diseases of the university hospital in Jena, Germany. All 
patients with newly diagnosed type 2 diabetes or problems 
with metabolic control were enrolled in the DTTP. Medica-
tion, type and frequency of self-monitoring, severe hypogly-
cemia, hemoglobin A1c (HbA1c), weight, and blood pressure 
were recorded before the DTTP and then at every visit, 
usually quarterly. We re-evaluated complete data sets from 
119 patients. Data were obtained from the electronic patient 
record EMIL® (v4.3.9.79; Marburg, Germany) were collected 
from general practitioners’ files. Data are described at baseline 
(before DTTP) and at 6 months, 12 months, and 24 months 
after participation in the DTTP. HbA1c was adjusted to DCCT 
standards with an evaluated standardization procedure using 
local reference ranges.13
Diabetes treatment and teaching program
The DTTP consists of four sessions once a week of 90–120 min-
utes, including interactive training. The topics of the DTTP are 
basic information about diabetes, postprandial self-monitoring 
of urine glucose, physiology and pathophysiology, hypocaloric 
nutrition, withdrawal of insulinotropic oral agents when unnec-
essary, foot care, hypoglycemia, and exercise (for details, see 
Table 1). Patients were trained to achieve glucose-free urine 
2 hours postprandially and to tailor the type and amount of 
their food accordingly. If postprandial glucosuria-free tests 
correlated with the desired level of metabolic control, this 
inexpensive testing was considered to be sufficient. The main 
teaching part of the DTTP was performed by diabetes educators 
(ie, nurses and dieticians with special postgraduate training).
Outcomes
Primary outcomes are changes in HbA1c, weight, and OADs 
24 months after training in the DTTP. A secondary outcome 
is the difference in HbA1c between self-monitoring of urine 
glucose and blood glucose.
Statistical analysis
Statistical analysis was performed with SPSS 14.0 (SPSS, Inc, 
Chicago, IL). Normally distributed values were registered as 
mean ± standard deviation and non-normally distributed values 
as median and range. Differences were statistically evaluated 
by t-test, Mann-Whitney U Test, or χ2 test. A P-value of ,0.05 
was considered to be statistically significant.
Results
From the initial 126 trained patients we were able to re-  evaluate 
119 (94%) after 24 months. At baseline, age was 61.5 years 
(±10.29 years), time since diagnosis of diabetes was 5.57 years 
(±6.53 years), body weight was 89.89 kg (±15.88 kg), body 
mass index was 32.23 kg/m2 (±5.74 kg/m2), and blood pres-
sure was 159/88 mmHg (±24.69/±12.18 mmHg). Of the 
patients, 39.4% (n = 47) were newly diagnosed with type 
2 diabetes, and 59.7% (n = 71) were still cared for in the 
university outpatient department.
HbA1c decreased significantly 6 months after educa-
tion from 7.33% (±1.59%) to 6.89% (±0.98%; P = 0.001 
Table 1 Structured treatment and teaching program
Education unit Information topic
Unit 1 What is diabetes? 
Postprandial urine glucose self-monitoring 
Hypoglycemia
Unit 2 Pathophysiology of diabetes 
Oral hypoglycemic agents 
Nonpharmacological therapy 
Calorie-defined diet 
Lifestyle changes
Unit 3 Diabetic neuropathy 
Foot care 
Physical activity
Unit 4 Sick-day rules 
Smoking 
Check-up for late complications
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Table 2 HbA1c and body weight according to diabetes therapy used at 24 months
Antidiabetic therapy  
at 24 months
HbA1c (%) Body weight (kg)
Baseline 24 months P-value Baseline 24 months P-value
All patients 7.33 6.96 0.001 89.9 88.5 0.001
No drug (19.3%) 6.42 6.49 NS 92.5 90.3* 0.014
OAD (52.1%) 7.14 6.88 NS 87.4 85.1* 0.001
Insulin (28.6%) 8.33 7.43* 0.01 92.7 93.7 0.088
Abbreviations: HbA1c, hemoglobin A1c; NS, not significant; OAD, oral antiglycemic drug.
versus baseline) and was maintained for up to 12 months 
(7.02 ± 1.07%; P = 0.017 versus baseline), as well as up to 
24 months (6.96 ± 1.06%; P = 0.005 versus baseline). Patients 
still attending our university outpatient department had a higher 
baseline HbA1c than patients of general practitioners (7.61% 
versus 6.94%; P = 0.024) and also a higher HbA1c 12 months 
(7.23% versus 6.69%; P = 0.008) and 24 months after   education 
(7.18% versus 6.65%; P = 0.007). HbA1c decreased in both 
groups, but the change was significant only in patients cared 
for at the university hospital (P = 0.027). At baseline, 49.6% 
of patients had an HbA1c of # 7% and 10.1% . 9%. Twelve 
months after participation in the DTTP, the number of patients 
with an HbA1c # 7% increased to 60.0% (P = 0.001), whereas 
the number with an HbA1c . 9% decreased to 3.5% (P = 0.069). 
These results were maintained after 24 months, with 58.8% 
  having an HbA1c # 7% and 5% . 9% (P = 0.112 versus base-
line). Body weight decreased significantly from 89.9 kg at base-
line to 87.8 kg after 6 months (P = 0.001), increased to 88.9 kg 
at 12 months (P = 0.001 versus baseline), and was 88.5 kg 
24 months later (–1.4 kg compared with baseline; P = 0.001). 
Blood pressure decreased from 159/87 mmHg to 140/81 mmHg 
(P = 0.001) 24 months after participation in the DTTP.
Antidiabetic medication
Changes in HbA1c and body weight are shown in Table 2, 
changes in HbA1c according to diabetes therapy at baseline 
and at 24 months are shown in Figure 1, and changes in 
body weight according to therapy are depicted in Figure 2. 
At baseline, 31.1% of the patients were not on antidiabetic 
medication (HbA1c 6.75%), and 68.9% were on OADs (HbA1c 
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Figure 1 Changes in HbA1c at 24 months according to antidiabetic therapy used at baseline (blue bars) and 24 months (green bars). 
Note: *P , 0.05.
Abbreviations: HbA1c, hemoglobin A1c; OAD, oral antiglycemic drug.
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Table 3 Methods of self-monitoring (percent patients) according to antidiabetic therapy used
Antidiabetic therapy  
at 24 months
No self-monitoring Urine glucose Blood glucose
Baseline 2 years Baseline 2 years Baseline 2 years
All patients 46.2 24.4 31.1 26.1 18.5 44.5
No drug 67.6 52.2 16.2 43.5 10.8 4.3
OAD 36.6 27.4 37.8 33.9 22.0 30.6
Insulin 2.9 97.1
Abbreviation: OAD, oral antiglycemic drug.
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Figure 2 Changes in body weight at 24 months according to antidiabetic therapy used at baseline (blue bars) and 24 months (green bars). 
Note: *P , 0.05.
Abbreviation: OAD, oral antiglycemic drug.
7.60%). Twenty-four months after the DTTP, 19.3% were 
still not on antidiabetic medication. The baseline HbA1c of 
this subgroup was 6.42% and remained constant (6.49% at 
24 months; not significant). The body weight of this group 
decreased significantly from 92.5 kg at baseline to 90.3 kg 
at 24 months (P = 0.014).
The HbA1c values of patients taking OADs at 24 months 
(52.1%) decreased slightly (7.14% at baseline; 6.88% at 
24 months; not significant), whereas body weight decreased 
significantly from 87.4 kg at baseline to 85.1 kg at 24 months 
(P = 0.001).
HbA1c of patients with insulin treatment at 24 months 
(28.6%) decreased significantly from 8.33% at baseline to 
7.43% (P = 0.011), but body weight increased from 92.7 kg 
to 93.7 kg (P = 0.088). Patients attending the university 
outpatient department were more often on insulin therapy at 
24 months than patients in the care of a general practitioner 
(43.7% versus 6.3%, P = 0.001).
Self-monitoring
The methods of self-monitoring according to diabetes 
therapy are shown in Table 3. Only 53.8% of the patients 
performed self-monitoring at baseline, compared with 
75.6% at 24 months. UGSM was performed at baseline by 
31.1% and at 24 months by 26.1%. BGSM was performed 
at baseline by 18.5% and at 24 months by 44.5%. Both 
methods, UGSM and BGSM, were used at baseline by 4.2% 
and at 24 months by 5.0%. Of those patients not on insulin 
therapy at 24 months, more preferred UGSM (36.5% versus 
23.5%, P = 0.048).
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There were differences concerning the self-monitoring 
method applied between those patients who were exclusively 
treated by a general practitioner and those who also attended 
the university outpatient department. All patients treated 
in the university outpatient department used one kind of self 
monitoring (UGSM or BGSM), but only 39.6% of patients 
treated by their general practitioner performed self monitor-
ing (P = 0.001). At 24 months, most patients not requiring 
insulin therapy and treated in the university outpatient 
department performed UGSM (UGSM 65%; BGSM 22.5%). 
This compares with those patients who were treated by their 
general practitioner with most of them performing BGSM 
(UGSM 11.1%; BGSM 24.4%). Comparing the HbA1c of 
those patients not requiring insulin therapy applying UGSM 
or BGSM, no difference was found either at baseline (7.23% 
versus 7.04%; P = 0.597) or at 24 months (6.91% versus 
6.87%; P = 0.855; Figure 3).
Discussion and conclusion
The first evaluation of DTTP for patients with type 2 diabetes 
not requiring insulin therapy was published in 1988.3 The 
program was primarily developed for general practitioners to 
improve care for diabetic patients. We studied the long-term 
effects of this program. The follow-up of the first evalua-
tion was 12 months. Patients had a significant reduction in 
bodyweight of 2 kg and the already good HbA1c at study 
entry did not deteriorate in spite of 30% less OADs used 
and none of the patients switching to insulin. The follow-
ing evaluations of this DTTP in Austria and Latin America 
showed reductions in HbA1c ranging from 0.4% to 1.1% after 
a follow-up of 6–12 months,4,16–18 and a body weight reduc-
tion of 2.5 kg. These favorable results are also shown in our 
study but with a considerably longer follow-up of 24 months. 
The recently published DESMOND (Diabetes Education 
and Self   Management for Ongoing and Newly Diagnosed) 
study in the UK evaluated the effectiveness of another group 
education program in people with newly diagnosed type 2 
diabetes mellitus19 and found that 12 months after education 
there was a greater weight reduction for those patients than 
for patients in the control group (−2.98 kg versus −1.86 kg), 
without there being a difference in HbA1c.
It is well known that a reduction in body weight reduces 
insulin resistance in patients with type 2 diabetes, which 
results in better metabolic control.3,8,14,18 In contrast to 
these results, patients in the UK Prospective Diabetes 
Study assigned to diet therapy only had weight gain and the 
worst HbA1c. The different results might be caused by the 
DTTP initiating behavior modification by the participating 
patients and the possibility of continuous feedback by self-
  monitoring. A further reason for encouraging results is the 
absence of a diet plan in the curriculum used in our study. 
Except for drinks with sugar and instant food, all nutrients 
are allowed. Type and amount of food corresponds to the 
endogenous insulin present and to the person’s individual 
insulin resistance if postprandial urine glucose tests are 
negative.
Lifestyle interventions are effective, particularly in obese 
type 2 diabetes patients, but, in the long term, insulin treatment 
will become necessary in many people with type 2   diabetes.15 
After 24 months, 29% of our patients were on insulin therapy. 
Initially, these patients had the worst baseline HbA1c but the 
greatest improvement in metabolic control. Before starting 
insulin therapy these patients took part in another DTTP 
conceived for patients with insulin therapy. All those patients 
switched to insulin after the first evaluation of this program 
after 12 months.3 In the evaluation from Pieber et al,4 no 
patient was on insulin therapy 6 months after   education. 
  However, the HbA1c value 6 months after education was 8.11% 
and considerably higher than in the study presented.
Not surprisingly, patients on insulin therapy gained 
weight, as was reported in other studies starting with insu-
lin treatment.15 However, weight gain was only 1 kg after 
2 years.
The number of sessions recommended in DTTPs is 
  debatable. The outcome of the DTTP with only four sessions 
is not worse compared with a program with eight or twelve 
sessions.8 This program decreased HbA1c from 8.1% to 7.4% 
and weight from 87.8 kg to 85.3 kg. The highest decrease 
of HbA1c was in patients on insulin, so the significant total 
HbA1c reduction mainly derives from the reduction in HbA1c 
of patients on insulin therapy. It was not the target of the DTTP 
to reduce the good HbA1c, which was already at baseline in 
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Figure 3 Hemoglobin A1c(HbA1c) according to the method of self-monitoring used 
at baseline and 24 months after participation in the diabetes treatment and teaching 
program (urine glucose self-monitoring [blue bars]; blood glucose self-monitoring 
[green bars]).
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the target. The aim for these patients was to maintain good 
HbA1c for longer, and this aim was achieved.
It is likely that it is not the number of sessions that is 
important but the delivery of the program by the team who 
is responsible for the permanent care of the patient. This is 
usually the family physician or general practitioner.
In the DTTP presented and evaluated, all patients not 
requiring insulin therapy are trained to perform postprandial 
urine tests for glucose. If postprandial urine is glucose free 
and matches the desired level of metabolic control after 
3–6 months, this inexpensive testing is considered to be suf-
ficient. Nevertheless, some subgroups may require BGSM (eg, 
patients with elevated or reduced renal threshold for glucose). 
Whether BGSM has any advantages in patients not requiring 
insulin therapy treatment has been repeatedly evaluated and 
discussed. In a retrospective study from Germany, Martin 
et al10 showed a decreased diabetes-related morbidity and 
all-cause mortality in type 2 diabetes patients who received 
a prescription of BGSM material in spite of higher HbA1c, 
compared with those not using BGSM, and this association 
was also present in a subgroup of patients not receiving insulin 
therapy. In the Fremantle study from Australia, Davis et al11 
did not find any difference in HbA1c in BGSM users or nonus-
ers, but BGSM was associated with a 79% increased risk of 
cardiovascular mortality in patients not treated with insulin.20 
In addition, a large survey from Austria and   Germany did 
not show any association between HbA1c and the frequency 
of BGSM in type 2 diabetic patients not requiring insulin 
therapy.21 In the randomized controlled trials by Miles et al9 
and the recently published DESMOND study, BGSM was not 
superior to UGSM in respect of no self-control in patients with 
newly diagnosed type 2 diabetes.12 The results of our study 
support those findings that UGSM is not inferior to BGSM 
in well-trained patients, considering that most patients not 
requiring insulin therapy performed UGSM and that no dif-
ference in HbA1c after 2 years was found.
The strongest limitation of our study is the lack of a 
control group. For ethical reasons, it is not possible to refuse 
patients participation in the DTTP over 2 years. Furthermore, 
there are already controlled trials that have shown the effec-
tiveness of the DTTP but over a shorter period.3,4 Another 
limitation is the possibility of a negative selection of patients, 
because we are a specialist university outpatient department. 
However, the good HbA1c of the patients is contradicted.
In summary, the results of our study showed that a treat-
ment and teaching program consisting of four sessions once 
a week effectively reduces HbA1c and weight over 2 years, 
irrespective of the method of self-monitoring applied.
Conclusion
Weight decreased significantly in patients with and without 
OADs. HbA1c of patients without OADs still met the target 
after 24 months. In patients on OADs, HbA1c fell 0.26% 
below the initial level. Twenty-nine percent of patients 
were on insulin therapy 24 months after the DTTP. Glu-
cose control (HbA1c) was similar with UGSM (7.03%) and 
BGSM (6.97%; P = 0.807) at 24 months. These findings 
suggest that postprandial urine testing is effective, as well 
as blood glucose control. More research is required to 
assess whether there is a difference in effectiveness between 
these types of self-monitoring. Patient education should be 
an integral part of the diabetes treatment, and all patients 
should have the opportunity to participate in the DTTP.
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